ARPA-H’s $144 million PROSPR program is testing rapamycin, semaglutide, and dapagliflozin in 726 healthy older adults, funding a first-in-humans trial of a retrotransposon-silencing HIV drug, and building a validated biological…
David Sinclair helped make longevity science impossible to ignore. He also became one of its most contested public figures. Part II examines the criticism, contradictory evidence, and scientific arguments that…
David Sinclair helped move aging research from the scientific margins into mainstream conversation. Through his Harvard lab, his work on sirtuins, NAD+ biology, epigenetic reprogramming, and his public role as…
Harvard researcher Marinka Zitnik is building AI systems designed to uncover hidden treatments for rare and neglected diseases. Her TxGNN work points toward a future where drug repurposing becomes more…
Every Cure is a nonprofit using AI and drug repurposing to uncover treatments hidden inside existing medicines. Founded by physician-scientist David Fajgenbaum after a repurposed drug saved his own life,…
ARK Invest dumped $87 million in Nvidia and Meta last week and redirected capital into Tempus AI, GeneDx Holdings, CRISPR Therapeutics, and other healthcare AI and genomics companies. The signal…
Two university-led advances point to the next chapter in AI-enabled drug discovery. MIT’s VibeGen designs proteins by their motion profiles. ASU’s fast sampling method accelerates access to conformational landscapes. Together,…
A Rock Health survey of 8,000 Americans and a Microsoft analysis of 500,000 Copilot conversations reveal a seismic shift in how people navigate symptoms, treatments, and the healthcare system itself….
A former Apple and Jawbone engineer built the first FDA-cleared wearable that simultaneously activates muscles and relaxes spasms, giving millions with MS, stroke, cerebral palsy, and spinal cord injuries the…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.